Literature DB >> 27997860

VEGF gene therapy cooperatively recruits molecules from the immune system and stimulates cell homing and angiogenesis in refractory angina.

Bruna Eibel1, Melissa M Markoski1, Clarissa G Rodrigues1, Thiago Dipp2, Felipe B de Salles3, Imarilde I Giusti1, Nance B Nardi4, Rodrigo D M Plentz5, Renato A K Kalil6.   

Abstract

BACKGROUND: New vessels are formed in response to stimuli from angiogenic factors, a process in which paracrine signaling is fundamental.
OBJECTIVE: To investigate the cooperative paracrine signaling profile in response to Vascular Endothelial Growth Factor (VEGF) gene therapy in patients with coronary artery disease (CAD) and refractory angina.
METHOD: A cohort study was conducted in which plasma was collected from patients who underwent gene therapy with a plasmid expressing VEGF 165 (10) and from surgical procedure controls (4). Blood samples were collected from both groups prior to baseline and on days 3, 9 and 27 after the interventions and subjected to systemic analysis of protein expression (Interleukin-6, IL-6; Tumor Necrosis Factor-α, TNF-α; Interleukin-10, IL-10; Stromal Derived Factor-1 α, SDF-1α; VEGF; Angiopoietin-1, ANGPT-1; and Endothelin-1, ET-1) using the enzyme-linked immunosorbent assay (ELISA).
RESULTS: Analysis showed an increase in proinflammatory IL-6 (p=0.02) and ET-1 (p=0.05) on day 3 after gene therapy and in VEGF (p=0.02) on day 9. A strong positive correlation was found between mobilization of endothelial progenitor cells and TNF-α on day 9 (r=0.71; p=0.03). Furthermore, a strong correlation between β-blockers, antiplatelets, and vasodilators with SDF-1α baseline in the group undergoing gene therapy was verified (r=0.74; p=0.004).
CONCLUSION: Analysis of cooperative paracrine signaling after VEGF gene therapy suggests that the immune system cell and angiogenic molecule expression as well as the endothelial progenitor cell mobilization are time-dependent, influenced by chronic inflammatory process and continuous pharmacological treatment. Copyright Â
© 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Angiogenesis; Cell homing; Coronary artery disease; Gene therapy; Refractory angina; Vascular endothelial growth factor

Mesh:

Substances:

Year:  2016        PMID: 27997860     DOI: 10.1016/j.cyto.2016.12.005

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  2 in total

1.  Recombinant adenovirus expressing a dendritic cell-targeted melanoma surface antigen for tumor-specific immunotherapy in melanoma mice model.

Authors:  Li-Li Guo; Gang-Cheng Wang; Peng-Jie Li; Cui-Mei Wang; Lin-Bo Liu
Journal:  Exp Ther Med       Date:  2018-04-23       Impact factor: 2.447

Review 2.  Gene therapy for refractory angina and cell therapy for heart failure: experience of a Brazilian research group.

Authors:  Roberto Tofani Sant'Anna; Bruna Eibel; Melissa Medeiros Markoski; Clarissa Garcia Rodrigues; Felipe Borsu de Salles; Imarilde Inês Giusti; Ivo Abrahão Nesralla; Nance Beyer Nardi; Renato Abdala Karam Kalil
Journal:  Gene Ther       Date:  2019-07-05       Impact factor: 5.250

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.